Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update Aug 05, 2026 ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026 Jul 29, 2026 ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update May 06, 2026 ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older May 04, 2026 ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026 Apr 29, 2026 ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research Mar 27, 2026 ADMA Biologics Addresses Misleading Short-Seller Report Mar 25, 2026 ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative Mar 02, 2026 ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Feb 25, 2026 ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 Feb 18, 2026
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update Aug 05, 2026
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update May 06, 2026
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older May 04, 2026
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research Mar 27, 2026
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative Mar 02, 2026
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Feb 25, 2026
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 Feb 18, 2026
